CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Heron Therapeutics Q3 net revenue falls 7.8%, to sell all assets to CorMedix

By Reuters News


Overview

  • US biotechnology company's Q3 net revenue fell 7.8% yr/yr to $35.3 mln

  • Acute care franchise revenue rose, but oncology supportive care revenue declined

  • Company agreed to sell substantially all assets to CorMedix, pending shareholder approval


Outlook

  • Company withdrew full-year 2026 financial guidance in August and is not providing guidance now

  • Company has agreed to sell substantially all assets to CorMedix Therapeutics, pending shareholder approval


Result Drivers

  • ACUTE CARE GROWTH - Revenue from acute care products, including ZYNRELEF and APONVIE, increased in Q3 2026

  • ONCOLOGY DECLINE - Oncology supportive care revenue fell, driven by lower CINVANTI sales and the end of SUSTOL commercial sales


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Product Sales

$35.25 mln


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."


Reuters Recommended Reads

  • Nov 9 - ImmunityBio Q3 revenue rises on Anktiva sales growth but misses estimates

  • Nov 9 - TG Therapeutics Q3 product revenue rises on BRIUMVI sales; lifts 2026 outlook

  • Nov 9 - Biopharma Almirall 9M sales rise on European dermatology growth


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.